Introduction

Pruritic Urticarial Papules and Plaques of Pregnancy (PUPPP) is one of the most common dermatological conditions affecting pregnant women, particularly during the third trimester. Characterised by intensely itchy, red, hive-like rashes, PUPPP typically begins in the abdominal stretch marks and can spread to the thighs, buttocks, and arms. Although visually alarming and physically uncomfortable, PUPPP is considered a benign condition with no known systemic implications for the mother or baby.

PUPPP most frequently occurs in first-time pregnancies and is more common in women carrying multiples (twins, triplets, or more), and those who experience rapid or excessive abdominal distension. The rash usually resolves spontaneously shortly after delivery, but the distress it causes during pregnancy can be significant.

Understanding maternal skin conditions like PUPPP is important not only for maternal comfort but also for assessing any potential implications to fetal health. While the appearance and symptoms of PUPPP can be concerning, current evidence indicates that this condition has no direct harmful effects on the fetus, making accurate diagnosis and effective management essential to ensure both maternal well-being and fetal safety.

Understanding PUPPP

Pruritic Urticarial Papules and Plaques of Pregnancy (PUPPP), also known as polymorphic eruption of pregnancy, is a benign, self-limiting skin condition that typically arises during the third trimester. It presents as red, raised, hive-like papules that often coalesce into plaques. The rash typically begins in the abdominal striae (stretch marks) and may spread to the thighs, buttocks, and arms. Notably, the periumbilical area is usually spared. The itching associated with PUPPP can be intense and is often the most distressing symptom for affected women.

PUPPP is estimated to affect approximately 1 in 160 to 1 in 300 pregnancies, making it the most common pregnancy-related dermatosis. It is more prevalent in first-time mothers and in women carrying multiple fetuses. Excessive abdominal distension is thought to contribute to its development, likely due to skin stretching and connective tissue stress.

Differentiating PUPPP from other pregnancy dermatoses such as pemphigoid gestationis, intrahepatic cholestasis of pregnancy, or atopic eruption of pregnancy is critical, as some of these conditions can have serious implications for fetal health. PUPPP, in contrast, does not involve systemic symptoms or autoimmune markers, helping clinicians confirm its benign nature.¹

Pathophysiology and triggers

The exact cause of PUPPP remains unclear, but several theories have been proposed to explain its development. One widely accepted hypothesis suggests that rapid abdominal stretching, particularly in the third trimester, leads to damage or inflammation in the connective tissue within the skin. This may trigger an immune response, resulting in the characteristic rash and itching. This could explain why PUPPP is more common in first pregnancies and in women with multiple gestations or significant weight gain.

Hormonal factors may also play a role, with elevated levels of progesterone and estrogen potentially influencing skin sensitivity and immune function during pregnancy. However, no consistent hormonal abnormalities have been identified in affected women.

Importantly, PUPPP is considered a localised inflammatory condition without systemic involvement. There is no evidence of autoimmunity or maternal organ dysfunction, and laboratory findings are typically normal. Because the inflammation is confined to the skin and does not affect the placenta or fetal circulation, there is no direct impact on fetal health. This localised nature distinguishes PUPPP from more serious dermatoses of pregnancy that may pose risks to the fetus.¹

Maternal impact of PUPPP

While PUPPP poses no direct risk to the fetus, its effects on the mother can be physically and emotionally challenging. The most prominent symptom is intense pruritus (itching), which often begins on the abdomen, particularly within stretch marks, and can spread to the thighs, buttocks, and arms. Though the rash is non-scarring and resolves after delivery, the discomfort it causes can be considerable.

The constant itching often leads to sleep disturbances, leaving expectant mothers fatigued and frustrated during an already demanding stage of pregnancy. Scratching may exacerbate the irritation, potentially causing skin breaks or secondary infections if not properly managed.

In addition to physical discomfort, PUPPP can take a psychological toll. The distress from persistent symptoms may contribute to anxiety, mood changes, and reduced quality of life in late pregnancy. Despite its benign nature, the daily burden of PUPPP highlights the importance of supportive care, symptom relief, and reassurance to help mothers cope with the condition while maintaining their well-being.

Fetal health considerations

Despite the alarming appearance and uncomfortable symptoms of PUPPP, current medical evidence consistently shows that the condition does not negatively impact fetal health. Numerous studies have assessed pregnancy outcomes in women diagnosed with PUPPP, and the findings are reassuring. Babies born to mothers with PUPPP typically have normal growth parameters, healthy birth weights, and standard APGAR scores, with no increase in the rates of preterm birth, intrauterine growth restriction, or neonatal complications.

One of the key distinguishing features of PUPPP is the absence of placental or intrauterine involvement. Unlike other pregnancy-related dermatoses, such as pemphigoid gestationis or intrahepatic cholestasis of pregnancy—which are associated with increased risks to the fetus — PUPPP remains a cutaneous condition, confined to the maternal skin. Laboratory tests and ultrasounds in PUPPP-affected pregnancies typically show no signs of fetal distress or abnormal development.

Because the inflammation in PUPPP is localised and non-systemic, there is no evidence of transplacental antibody transfer or immunological compromise to the fetus. As a result, obstetricians can confidently reassure affected patients that while the condition may cause significant maternal discomfort, it poses no direct threat to the unborn child. This makes accurate diagnosis and patient education essential components of care.²

Safety profile of PUPPP

PUPPP is widely recognised as a benign dermatological condition of pregnancy with no long-term consequences for either the mother or fetus. Despite its distressing symptoms, it remains a self-limiting rash that typically resolves within days to weeks after delivery. The absence of systemic symptoms or internal organ involvement makes PUPPP a relatively benign condition compared to other dermatoses of pregnancy.

A crucial aspect of managing PUPPP is differentiating it from other pruritic conditions that do carry fetal risks. For instance, pemphigoid gestationis is an autoimmune blistering disorder associated with preterm birth and small-for-gestational-age infants. Intrahepatic cholestasis of pregnancy, another important differential diagnosis, is linked to increased rates of stillbirth and requires immediate medical intervention. Unlike these conditions, PUPPP does not affect liver function or involve immune-mediated placental damage.

Because of these important distinctions, an accurate and timely diagnosis is essential. Clinicians must evaluate symptoms carefully and, when necessary, conduct appropriate tests to exclude other diagnoses. Recognising the benign nature of PUPPP allows for conservative management, focusing on maternal comfort without unnecessary interventions or anxiety about fetal safety. Educating patients on the harmless nature of the rash can also alleviate fears and improve the overall pregnancy experience.¹

Treatment and management implications for fetal well-being

The management of PUPPP centres on relieving maternal symptoms while ensuring the safety of the fetus. Since the condition is benign and self-limiting, treatment typically involves topical therapies and supportive care rather than systemic medications. Topical corticosteroids are the first-line treatment, effectively reducing inflammation and itching. When used in low to moderate doses and applied correctly, these are considered safe in pregnancy and pose minimal risk to fetal health.³

Oral antihistamines may also be prescribed to manage pruritus (itchy skin), especially at night. Commonly used antihistamines like diphenhydramine and loratadine have acceptable safety profiles during pregnancy, although their use should always be discussed with a healthcare provider to ensure appropriateness for each individual case.

Non-invasive symptom relief strategies—such as cool baths, moisturisers, oatmeal-based products, and loose clothing—can also significantly improve comfort without posing any risk to the fetus. In most cases, these conservative measures, along with reassurance, are sufficient.

Healthcare providers need to weigh maternal comfort against fetal safety when considering any pharmacologic treatment. Fortunately, the options commonly used for PUPPP offer effective symptom relief without compromising fetal well-being, supporting the continued use of conservative approaches in managing this condition.⁴

Monitoring and prenatal care considerations

Routine prenatal care remains unchanged in pregnancies affected by PUPPP, as the condition does not involve systemic illness or fetal compromise. There is no indication for additional fetal surveillance, such as increased ultrasounds or non-stress tests, solely based on the presence of PUPPP.

However, proper diagnosis is essential to rule out more serious dermatoses of pregnancy that may require closer fetal monitoring and intervention. If symptoms suggest a condition like pemphigoid gestationis or cholestasis of pregnancy, further evaluation, including laboratory tests and dermatological consultation, may be warranted.

In most cases, PUPPP can be managed entirely by obstetricians or general practitioners. However, interdisciplinary collaboration with dermatologists may be helpful in more severe cases or when the diagnosis is uncertain. Patient education is key—reassuring the mother of the harmless nature of the condition can reduce stress and improve compliance with conservative management strategies.

Overall, PUPPP does not necessitate changes to standard obstetric care and can be managed effectively without additional fetal monitoring, provided other risks are ruled out.⁵

Summary

Pruritic Urticarial Papules and Plaques of Pregnancy (PUPPP) is a common, benign skin condition that affects pregnant women—mostly first-time mothers or those with multiple gestations—during the third trimester. It causes intensely itchy, red rashes, mainly on the abdomen, but has no direct or harmful effects on fetal health.

Unlike other pregnancy-related skin disorders like pemphigoid gestationis or intrahepatic cholestasis, PUPPP is localised to the skin, involves no systemic inflammation, and does not affect the placenta or fetal circulation. Babies born to mothers with PUPPP generally have normal birth outcomes, including healthy weight and APGAR scores.

The primary concern is maternal discomfort, which may lead to sleep disturbances and emotional stress. Treatment focuses on symptom relief using safe topical corticosteroids, antihistamines, and non-medicated remedies like cool baths and moisturisers. No additional fetal monitoring is needed unless other conditions are suspected.

Accurate diagnosis is crucial to distinguish PUPPP from more serious conditions, ensuring appropriate care and minimising unnecessary interventions. Educating patients on its harmless nature supports better maternal well-being during pregnancy.

FAQs

Does PUPPP rash harm the baby?

No, PUPPP does not harm the baby.
PUPPP is a skin condition that affects only the mother. It does not involve the placenta, uterus, or fetal circulation. Studies have shown no increase in adverse outcomes such as preterm birth, low birth weight, or fetal distress in pregnancies affected by PUPPP.

Can PUPPP cause complications during labour or delivery?

No, PUPPP does not interfere with labour or delivery.
The rash typically resolves shortly after childbirth and does not affect uterine function or delivery outcomes. Labour can proceed normally unless there are other unrelated medical issues present.

Is it safe to use medications like corticosteroids or antihistamines for PUPPP during pregnancy?

Yes, when used appropriately.
Low- to moderate-strength topical corticosteroids and certain antihistamines (such as loratadine or diphenhydramine) are generally considered safe during pregnancy. However, they should be used under medical supervision to ensure both maternal and fetal safety.

Will my baby be born with the rash?

No, the rash does not affect the baby’s skin.
PUPPP is not contagious or infectious and does not pass to the baby. Newborns of mothers with PUPPP are typically healthy and unaffected by the condition.

Can PUPPP recur in future pregnancies?

Recurrence is possible but uncommon.
PUPPP most often occurs in first-time pregnancies. While it can recur, especially in pregnancies involving multiples, many women do not experience it again in subsequent pregnancies.